Regardless of the excessive sensitivity of renal cell carcinoma (RCC) to immunotherapy, RCC has been acknowledged as an uncommon illness wherein CD8+ T-cell infiltration into the tumor beds is said to a poor prognosis. To strategy the interior panorama of immunobiology of RCC, we carried out multiplexed seven-color immunohistochemistry, which revealed the automated single-cell counts and calculations of particular person cell-to-cell distances.
In whole, 186 topics have been included, wherein CD39 was used as a marker for distinguishing tumor-specific (CD39+) and bystander (CD39–) T-cells. Our clear cell RCC cohort additionally revealed a poor prognosis if the tumor confirmed elevated CD8+ T-cell infiltration. Intratumoral CD8+CD39+ T-cells in addition to their exhausted CD8+CD39+PD-1+ T-cells within the central tumor areas enabled the subgrouping of sufferers in response to malignancy.
Evaluation utilizing specimens post-antiangiogenic therapy revealed a dramatic improve in proliferative Treg fraction Foxp3+PD-1+ cells, suggesting a possible mechanism of hyperprogressive illness after makes use of of anti-PD-1 antibody. Our cell-by-cell research platform supplied spatial info on tumors, the place bystander CD8+CD39– T-cells have been dominant within the invasive margin areas.
We uncovered a possible interplay between CD8+CD39+PD-1+ T-cells and Foxp3+PD-1+ Treg cells because of cell-to-cell proximity, forming a spatial area of interest extra specialised in immunosuppression beneath PD-1 blockade. A paradigm shift to the immunosuppressive surroundings was extra apparent in metastatic lesions; quite the infiltration of Foxp3+ and Foxp3+PD-1+ Treg cells was extra pronounced. With this multiplexed single-cell pathology approach, we revealed additional perception into the immunobiological standing of RCC.
Pulmonary Giant Cell Neuroendocrine Carcinoma: A Uncommon Kind of Non-Small Cell Lung Most cancers
Pulmonary massive cell neuroendocrine carcinoma (LCNEC) is an unusual kind of non-small cell lung most cancers (NSCLC) with an incidence of roughly 3% of all lung most cancers diagnoses. The affected person was a 60-year-old male with a 90-pack yr smoking historical past who offered with dyspnea on exertion and productive cough for 5 weeks.
Decreased breath sounds with out respiratory misery and generalized cachexia have been famous on the preliminary bodily examination. Laboratory outcomes have been unremarkable aside from continual microcytic anemia. Computed tomography revealed in depth lymphadenopathy of the paratracheal, paraaortic, hilar, and nodes surrounding the left pulmonary arteries.
Moreover, there have been areas of necrosis within the left higher lobe, lingula, and left decrease lobe with in depth pleural thickening extending to the stomach and subcutaneous tissue of the anterior chest wall. Biopsy and marking confirmed disorganized tight cell clusters with irregular and outstanding nuclei and quite a few lymphocytes according to LCNEC.
Immunohistochemistry was constructive for neural cell adhesion molecule CD56 and synaptophysin, which was indicative of neuroendocrine origin. It was additionally constructive for pan–cytokeratin antibody AE1 and AE3 and cytokeratin (CAM) 5.2, which come up from epithelial origin according to NSCLCs. Lastly, the affected person’s tissue was constructive for thyroid transcription factor-1, which confirmed the tumor’s major lung origin. This mixture of neuroendocrine and first lung tumor markers, along with the histology, confirmed the affected person’s prognosis of LCNEC.
The Position of a Minimal Immunohistochemical Antibody Panel in Confirming Undifferentiated Nasopharyngeal Carcinoma: A Cross-Sectional Examine on the Muhimbili Nationwide Hospital, Dar-es-Salaam, Tanzania.
Nasopharyngeal carcinoma (NPC) is a malignant epithelial neoplasm arising within the nasopharyngeal mucosa that exhibits mild microscopic and/or ultrastructural proof of squamous differentiation. Immunohistochemistry (IHC) can be utilized to reliably distinguish undifferentiated NPC from different malignant tumors, and the approach could also be a essential software towards the arrival of a definitive prognosis, notably when coping with difficult circumstances.
This was a cross-sectional hospital-based research which was performed at Muhimbili Nationwide Hospital. The research concerned 120 sufferers with NPC who have been identified on histopathological foundation between 2009 and 2013.The sensitivity and specificity of hematoxylin and eosin (H and E) stain in diagnosing NPC have been 99% and 30.4%, respectively. The accuracy of H and E stain to diagnose NPC and lymphoma was 94.2% and 30.4%, respectively.
CD45 antibody helped to verify 16 circumstances which have been identified as NPC on H and E stain to be lymphoma. Additional, AE1/AE3 antibody helped to verify one case who was identified as rhabdomyosarcoma on H and E stain to be NPC.The sensitivity and accuracy of H and E stains to diagnose NPC have been very excessive whereas the specificity was very low.
A big proportion of beforehand identified NPC circumstances by routine H and E stains have been confirmed to not be so by a minimal IHC antibody panel of pan–cytokeratin cocktail (AE1/AE3) and leukocyte frequent antigen (CD45). This highlights the paramount significance of a minimal IHC panel in helping to acquire a definitive prognosis in difficult circumstances of NPC.
Immunohistochemical Evaluation of a Vitreous Membrane Faraway from a Affected person with Incontinentia Pigmenti-Associated Retinal Detachment.
This can be a case historical past of a 23-year-old girl affected by incontinentia pigmenti (IP). The affected person’s imaginative and prescient within the left eye began to deteriorate because of cataract development on the age of 22, and by the age of 23, it dropped from 0.9 to 0.04. Ultrasound examination confirmed tractional vitreoretinal membranes.
Vitrectomy was carried out, due to this fact, on her left eye. The histological analysis of vitreous membrane revealed a fancy immunophenotype (positivity for glial fibrillary acidic protein (GFAP), vimentin, S-100, anti-pan cytokeratin antibody (AE/AE3), and easy muscle-specific actin (SMA) to varied extents).
The precise eye remained unsymptomatic all through this course. Apart from being the primary to investigate the tractional vitreoretinal membrane in IP with immunohistochemical strategies, this case research factors out that excessive circumstances of uneven facet involvement in IP do exist, even to the purpose of 1 eye being utterly unsymptomatic.
Dimension and Form Filtering of Malignant Cell Clusters inside Breast Tumors Identifies Scattered Particular person Epithelial Cells because the Most Worthwhile Histomorphological Clue within the Prognosis of Distant Metastasis Danger.
Survival and life high quality of breast most cancers sufferers could possibly be improved by extra aggressive chemotherapy for these at excessive metastasis threat and fewer intense therapies for low-risk sufferers. Such personalised therapy can’t be at the moment achieved because of the inadequate reliability of metastasis threat prognosis.
The aim of this research was due to this fact, to establish novel histopathological prognostic markers of metastasis threat by exhaustive computational picture evaluation of 80 measurement and form subsets of epithelial clusters in breast tumors. The group of 102 sufferers had a follow-up median of 12.Three years, with out lymph node unfold and systemic therapies. Epithelial cells have been stained by the AE1/AE3 pan–cytokeratin antibody cocktail.
The scale and form subsets of the stained epithelial cell clusters have been outlined in every picture by use of the circularity and measurement filters and analyzed for prognostic efficiency. Epithelial areas with the optimum prognostic efficiency have been uniformly small and spherical and could possibly be acknowledged as particular person epithelial cells scattered in tumor stroma.
Anti-Cytokeratin, Pan antibody |
|||
| STJ180154 | St John's Laboratory | 0.1 ml | EUR 254.4 |
Anti-Cytokeratin, Pan antibody |
|||
| STJ180390 | St John's Laboratory | 0.1 ml | EUR 276 |
Pan Cytokeratin Antibody Cocktail |
|||
| V9361-100UG | NSJ Bioreagents | 100ug | EUR 499 |
|
Description: PCK/4933R demonstrates a broad spectrum of cytokeratin reactivity. In normal tissues, PCK/4933R is reactive with most epithelial types, including bile ducts and hepatocytes in liver, bladder epithelium, breast ducts, bronchial epithelium, endometrium, intestinal epithelium of stomach, duodenum, ileum, colon, rectum, pancreas, ovarian epithelium, pancreatic acini, pituitary acini, pneumocytes, prostate, thyroid, skin (positive on the basal layer and negative on the superficial layers of squamous epithelium), and apocrine and sweat glands. In tumors, PCK/4933R is reactive with most carcinomas, including breast, transitional cell (TCC), renal cell (RCC), lung adenocarcinoma, lung small cell, lung squamous cell, endometrial, prostate, ovarian, hepatocellular (HCC), colorectal CA, stomach and thyroid. It is negative in certain normal tissues, including brain, lymphocytes and all cells of hematolymphoid origin, muscle, brain, nerves, endothelium and in certain tumors including most melanomas, sarcomas, lymphomas, primitive neuroectodermal tumors (PNET)/Ewings and gastrointestinal stromal tumors (GIST). Positivity has been seen on some dendritic cells in lymph nodes, some endothelia, and some muscle cells. |
|||
Pan Cytokeratin Antibody Cocktail |
|||
| V9361-20UG | NSJ Bioreagents | 20ug | EUR 219 |
|
Description: PCK/4933R demonstrates a broad spectrum of cytokeratin reactivity. In normal tissues, PCK/4933R is reactive with most epithelial types, including bile ducts and hepatocytes in liver, bladder epithelium, breast ducts, bronchial epithelium, endometrium, intestinal epithelium of stomach, duodenum, ileum, colon, rectum, pancreas, ovarian epithelium, pancreatic acini, pituitary acini, pneumocytes, prostate, thyroid, skin (positive on the basal layer and negative on the superficial layers of squamous epithelium), and apocrine and sweat glands. In tumors, PCK/4933R is reactive with most carcinomas, including breast, transitional cell (TCC), renal cell (RCC), lung adenocarcinoma, lung small cell, lung squamous cell, endometrial, prostate, ovarian, hepatocellular (HCC), colorectal CA, stomach and thyroid. It is negative in certain normal tissues, including brain, lymphocytes and all cells of hematolymphoid origin, muscle, brain, nerves, endothelium and in certain tumors including most melanomas, sarcomas, lymphomas, primitive neuroectodermal tumors (PNET)/Ewings and gastrointestinal stromal tumors (GIST). Positivity has been seen on some dendritic cells in lymph nodes, some endothelia, and some muscle cells. |
|||
Pan Cytokeratin Antibody Cocktail |
|||
| V9361SAF-100UG | NSJ Bioreagents | 100ug | EUR 499 |
|
Description: PCK/4933R demonstrates a broad spectrum of cytokeratin reactivity. In normal tissues, PCK/4933R is reactive with most epithelial types, including bile ducts and hepatocytes in liver, bladder epithelium, breast ducts, bronchial epithelium, endometrium, intestinal epithelium of stomach, duodenum, ileum, colon, rectum, pancreas, ovarian epithelium, pancreatic acini, pituitary acini, pneumocytes, prostate, thyroid, skin (positive on the basal layer and negative on the superficial layers of squamous epithelium), and apocrine and sweat glands. In tumors, PCK/4933R is reactive with most carcinomas, including breast, transitional cell (TCC), renal cell (RCC), lung adenocarcinoma, lung small cell, lung squamous cell, endometrial, prostate, ovarian, hepatocellular (HCC), colorectal CA, stomach and thyroid. It is negative in certain normal tissues, including brain, lymphocytes and all cells of hematolymphoid origin, muscle, brain, nerves, endothelium and in certain tumors including most melanomas, sarcomas, lymphomas, primitive neuroectodermal tumors (PNET)/Ewings and gastrointestinal stromal tumors (GIST). Positivity has been seen on some dendritic cells in lymph nodes, some endothelia, and some muscle cells. |
|||
Pan Cytokeratin Antibody Cocktail |
|||
| V9362-100UG | NSJ Bioreagents | 100ug | EUR 499 |
|
Description: Anti-cytokeratin clone rPCK/6750 demonstrates a broad spectrum of cytokeratin reactivity. In normal tissues, rPCK/6750 is reactive with most epithelial types, including bile ducts and hepatocytes in liver, bladder epithelium, breast ducts, bronchial epithelium, endometrium, intestinal epithelium of stomach, duodenum, ileum, colon, rectum, pancreas, ovarian epithelium, pancreatic acini, pituitary acini, pneumocytes, prostate, thyroid, skin (positive on the basal layer and negative on the superficial layers of squamous epithelium), and apocrine and sweat glands. In tumors, rPCK/6750 is reactive with most carcinomas, including breast, transitional cell (TCC), renal cell (RCC), lung adenocarcinoma, lung small cell, lung squamous cell, endometrial, prostate, ovarian, hepatocellular (HCC), colorectal CA, stomach and thyroid. It is negative in certain normal tissues, including brain, lymphocytes and all cells of hematolymphoid origin, muscle, brain, nerves, endothelium and in certain tumors including most melanomas, sarcomas, lymphomas, primitive neuroectodermal tumors (PNET)/Ewings and gastrointestinal stromal tumors (GIST). Positivity has been seen on some dendritic cells in lymph nodes, some endothelia, and some muscle cells. |
|||
Pan Cytokeratin Antibody Cocktail |
|||
| V9362-20UG | NSJ Bioreagents | 20ug | EUR 219 |
|
Description: Anti-cytokeratin clone rPCK/6750 demonstrates a broad spectrum of cytokeratin reactivity. In normal tissues, rPCK/6750 is reactive with most epithelial types, including bile ducts and hepatocytes in liver, bladder epithelium, breast ducts, bronchial epithelium, endometrium, intestinal epithelium of stomach, duodenum, ileum, colon, rectum, pancreas, ovarian epithelium, pancreatic acini, pituitary acini, pneumocytes, prostate, thyroid, skin (positive on the basal layer and negative on the superficial layers of squamous epithelium), and apocrine and sweat glands. In tumors, rPCK/6750 is reactive with most carcinomas, including breast, transitional cell (TCC), renal cell (RCC), lung adenocarcinoma, lung small cell, lung squamous cell, endometrial, prostate, ovarian, hepatocellular (HCC), colorectal CA, stomach and thyroid. It is negative in certain normal tissues, including brain, lymphocytes and all cells of hematolymphoid origin, muscle, brain, nerves, endothelium and in certain tumors including most melanomas, sarcomas, lymphomas, primitive neuroectodermal tumors (PNET)/Ewings and gastrointestinal stromal tumors (GIST). Positivity has been seen on some dendritic cells in lymph nodes, some endothelia, and some muscle cells. |
|||
Pan Cytokeratin Antibody Cocktail |
|||
| V9362SAF-100UG | NSJ Bioreagents | 100ug | EUR 499 |
|
Description: Anti-cytokeratin clone rPCK/6750 demonstrates a broad spectrum of cytokeratin reactivity. In normal tissues, rPCK/6750 is reactive with most epithelial types, including bile ducts and hepatocytes in liver, bladder epithelium, breast ducts, bronchial epithelium, endometrium, intestinal epithelium of stomach, duodenum, ileum, colon, rectum, pancreas, ovarian epithelium, pancreatic acini, pituitary acini, pneumocytes, prostate, thyroid, skin (positive on the basal layer and negative on the superficial layers of squamous epithelium), and apocrine and sweat glands. In tumors, rPCK/6750 is reactive with most carcinomas, including breast, transitional cell (TCC), renal cell (RCC), lung adenocarcinoma, lung small cell, lung squamous cell, endometrial, prostate, ovarian, hepatocellular (HCC), colorectal CA, stomach and thyroid. It is negative in certain normal tissues, including brain, lymphocytes and all cells of hematolymphoid origin, muscle, brain, nerves, endothelium and in certain tumors including most melanomas, sarcomas, lymphomas, primitive neuroectodermal tumors (PNET)/Ewings and gastrointestinal stromal tumors (GIST). Positivity has been seen on some dendritic cells in lymph nodes, some endothelia, and some muscle cells. |
|||
Cytokeratin (Pan-reactive) Antibody (PE) |
|||
| abx140315-01mg | Abbexa | 0.1 mg | EUR 627.6 |
Cytokeratin (Pan-reactive) Antibody (APC) |
|||
| abx140316-01mg | Abbexa | 0.1 mg | EUR 627.6 |
Cytokeratin (Pan-reactive) Antibody (Biotin) |
|||
| abx140317-01mg | Abbexa | 0.1 mg | EUR 510 |
Cytokeratin (Pan-reactive) Antibody (FITC) |
|||
| abx140318-01mg | Abbexa | 0.1 mg | EUR 560.4 |
Cytokeratin (Pan) (CK-5) Antibody |
|||
| abx015732-100ul | Abbexa | 100 ul | EUR 493.2 |
Cytokeratin (Pan) (CK-5) Antibody |
|||
| abx015736-100ul | Abbexa | 100 ul | EUR 493.2 |
anti-Cytokeratin (Pan) (7H8C4) |
|||
| LF-MA30121 | Abfrontier | 100 ul | EUR 583.2 |
|
Description: Mouse Monoclonal to Cytokeratin (Pan) |
|||
anti-Cytokeratin(Pan) (7H8) |
|||
| LF-MA30276 | Abfrontier | 100 ul | EUR 583.2 |
|
Description: Mouse Monoclonal to Cytokeratin(Pan) |
|||
Cytokeratin-pan (Acetyl Lys194) Polyclonal Antibody |
|||
| ABP50118-003ml | Abbkine | 0.03ml | EUR 189.6 |
|
Description: A polyclonal antibody for detection of Cytokeratin-pan Acetyl Lys194) from Human, Mouse, Rat. This Cytokeratin-pan Acetyl Lys194) antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Cytokeratin around the acetylation site of K194 |
|||
Cytokeratin-pan (Acetyl Lys194) Polyclonal Antibody |
|||
| ABP50118-01ml | Abbkine | 0.1ml | EUR 346.8 |
|
Description: A polyclonal antibody for detection of Cytokeratin-pan Acetyl Lys194) from Human, Mouse, Rat. This Cytokeratin-pan Acetyl Lys194) antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Cytokeratin around the acetylation site of K194 |
|||
Cytokeratin-pan (Acetyl Lys194) Polyclonal Antibody |
|||
| ABP50118-02ml | Abbkine | 0.2ml | EUR 496.8 |
|
Description: A polyclonal antibody for detection of Cytokeratin-pan Acetyl Lys194) from Human, Mouse, Rat. This Cytokeratin-pan Acetyl Lys194) antibody is for WB, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from human Cytokeratin around the acetylation site of K194 |
|||
Monoclonal Cytokeratin(Pan) Antibody, Clone: 7H8 |
|||
| AMM05824G | Leading Biology | 0.1ml | EUR 580.8 |
|
Description: A Monoclonal antibody against Human Cytokeratin(Pan). The antibodies are raised in Mouse and are from clone 7H8. This antibody is applicable in IHC, ICC, E |
|||
Cytokeratin-pan (Acetyl Lys194) Polyclonal Antibody |
|||
| ES1117-100ul | ELK Biotech | 100ul | EUR 334.8 |
|
Description: A Rabbit Polyclonal antibody against Cytokeratin-pan (Acetyl Lys194) from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA |
|||
Cytokeratin-pan (Acetyl Lys194) Polyclonal Antibody |
|||
| ES1117-50ul | ELK Biotech | 50ul | EUR 248.4 |
|
Description: A Rabbit Polyclonal antibody against Cytokeratin-pan (Acetyl Lys194) from Human/Mouse/Rat. This antibody is tested and validated for WB, ELISA, WB, ELISA |
|||
Anti-Cytokeratin, pan (Epithelial Marker) Antibody |
|||
| M14209-3 | BosterBio | 100ug/vial | EUR 476.4 |
|
Description: Rabbit Polyclonal Cytokeratin, pan (Epithelial Marker) Antibody. Validated in IHC and tested in Human. |
|||
Anti-Cytokeratin, pan (Epithelial Marker) Antibody |
|||
| M30944 | BosterBio | 100ug/vial | EUR 476.4 |
|
Description: Mouse Monoclonal Cytokeratin, pan (Epithelial Marker) Antibody. Validated in IHC and tested in Bovine, Canine, Chicken, Human, Monkey, Mouse, Rabbit, Rat. |
|||
Cytokeratin-pan (Acetyl-Lys194) Polyclonal Antibody |
|||
| HW128-100ul | SAB | 100ul | EUR 302.4 |
Cytokeratin-pan (Acetyl-Lys194) Polyclonal Antibody |
|||
| HW128-50ul | SAB | 50ul | EUR 224.4 |
Anti-Cytokeratin-pan (Acetyl K194) antibody |
|||
| STJ90157 | St John's Laboratory | 200 µl | EUR 236.4 |
|
Description: Rabbit polyclonal to Acetyl-Cytokeratin-pan (K194). |
|||
Pan Cytokeratin Antibody Cocktail (Acidic + Basic) |
|||
| V8321-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: Anti-cytokeratin clone PCK/3150 demonstrates a broad spectrum of cytokeratin reactivity. In normal tissues, PCK/3150 is reactive with most epithelial types, including bile ducts and hepatocytes in liver, bladder epithelium, breast ducts, bronchial epithelium, endometrium, intestinal epithelium of stomach, duodenum, ileum, colon, rectum, pancreas, ovarian epithelium, pancreatic acini, pituitary acini, pneumocytes, prostate, thyroid, skin (positive on the basal layer and negative on the superficial layers of squamous epithelium), and apocrine and sweat glands. In tumors, PCK/3150 is reactive with most carcinomas, including breast, transitional cell (TCC), renal cell (RCC), lung adenocarcinoma, lung small cell, lung squamous cell, endometrial, prostate, ovarian, hepatocellular (HCC), colorectal CA, stomach and thyroid. It is negative in certain normal tissues, including brain, lymphocytes and all cells of hematolymphoid origin, muscle, brain, nerves, endothelium and in certain tumors including most melanomas, sarcomas, lymphomas, primitive neuroectodermal tumors (PNET)/Ewings and gastrointestinal stromal tumors (GIST). Positivity has been seen on some dendritic cells in lymph nodes, some endothelia, and some muscle cells. |
|||
Pan Cytokeratin Antibody Cocktail (Acidic + Basic) |
|||
| V8321-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: Anti-cytokeratin clone PCK/3150 demonstrates a broad spectrum of cytokeratin reactivity. In normal tissues, PCK/3150 is reactive with most epithelial types, including bile ducts and hepatocytes in liver, bladder epithelium, breast ducts, bronchial epithelium, endometrium, intestinal epithelium of stomach, duodenum, ileum, colon, rectum, pancreas, ovarian epithelium, pancreatic acini, pituitary acini, pneumocytes, prostate, thyroid, skin (positive on the basal layer and negative on the superficial layers of squamous epithelium), and apocrine and sweat glands. In tumors, PCK/3150 is reactive with most carcinomas, including breast, transitional cell (TCC), renal cell (RCC), lung adenocarcinoma, lung small cell, lung squamous cell, endometrial, prostate, ovarian, hepatocellular (HCC), colorectal CA, stomach and thyroid. It is negative in certain normal tissues, including brain, lymphocytes and all cells of hematolymphoid origin, muscle, brain, nerves, endothelium and in certain tumors including most melanomas, sarcomas, lymphomas, primitive neuroectodermal tumors (PNET)/Ewings and gastrointestinal stromal tumors (GIST). Positivity has been seen on some dendritic cells in lymph nodes, some endothelia, and some muscle cells. |
|||
Pan Cytokeratin Antibody Cocktail (Acidic + Basic) |
|||
| V8321SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: Anti-cytokeratin clone PCK/3150 demonstrates a broad spectrum of cytokeratin reactivity. In normal tissues, PCK/3150 is reactive with most epithelial types, including bile ducts and hepatocytes in liver, bladder epithelium, breast ducts, bronchial epithelium, endometrium, intestinal epithelium of stomach, duodenum, ileum, colon, rectum, pancreas, ovarian epithelium, pancreatic acini, pituitary acini, pneumocytes, prostate, thyroid, skin (positive on the basal layer and negative on the superficial layers of squamous epithelium), and apocrine and sweat glands. In tumors, PCK/3150 is reactive with most carcinomas, including breast, transitional cell (TCC), renal cell (RCC), lung adenocarcinoma, lung small cell, lung squamous cell, endometrial, prostate, ovarian, hepatocellular (HCC), colorectal CA, stomach and thyroid. It is negative in certain normal tissues, including brain, lymphocytes and all cells of hematolymphoid origin, muscle, brain, nerves, endothelium and in certain tumors including most melanomas, sarcomas, lymphomas, primitive neuroectodermal tumors (PNET)/Ewings and gastrointestinal stromal tumors (GIST). Positivity has been seen on some dendritic cells in lymph nodes, some endothelia, and some muscle cells. |
|||
Pan Cytokeratin Antibody Cocktail (Acidic + Basic) |
|||
| V8774-100UG | NSJ Bioreagents | 100ug | EUR 499 |
|
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This antibody cocktail recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, which 67kDa (CK1); 64kDa (CK3); 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 50kDa (CK14); 50kDa (CK15); 48kDa (CK16); 40kDa (CK19). Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis. AE-1/AE-3 is a broad spectrum anti pan-cytokeratin antibody cocktail, which differentiates epithelial tumors from non-epithelial tumors e.g. squamous vs. adenocarcinoma of the lung, liver carcinoma, breast cancer, and esophageal cancer. It has been used to characterize the source of various neoplasms and to study the distribution of cytokeratin containing cells in epithelia during normal development and during the development of epithelial neoplasms. This antibody stains cytokeratins present in normal and abnormal human tissues and has shown high sensitivity in the recognition of epithelial cells and carcinomas. |
|||
Pan Cytokeratin Antibody Cocktail (Acidic + Basic) |
|||
| V8774-20UG | NSJ Bioreagents | 20ug | EUR 219 |
|
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This antibody cocktail recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, which 67kDa (CK1); 64kDa (CK3); 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 50kDa (CK14); 50kDa (CK15); 48kDa (CK16); 40kDa (CK19). Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis. AE-1/AE-3 is a broad spectrum anti pan-cytokeratin antibody cocktail, which differentiates epithelial tumors from non-epithelial tumors e.g. squamous vs. adenocarcinoma of the lung, liver carcinoma, breast cancer, and esophageal cancer. It has been used to characterize the source of various neoplasms and to study the distribution of cytokeratin containing cells in epithelia during normal development and during the development of epithelial neoplasms. This antibody stains cytokeratins present in normal and abnormal human tissues and has shown high sensitivity in the recognition of epithelial cells and carcinomas. |
|||
Pan Cytokeratin Antibody Cocktail (Acidic + Basic) |
|||
| V8774SAF-100UG | NSJ Bioreagents | 100ug | EUR 499 |
|
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This antibody cocktail recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, which 67kDa (CK1); 64kDa (CK3); 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 50kDa (CK14); 50kDa (CK15); 48kDa (CK16); 40kDa (CK19). Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis. AE-1/AE-3 is a broad spectrum anti pan-cytokeratin antibody cocktail, which differentiates epithelial tumors from non-epithelial tumors e.g. squamous vs. adenocarcinoma of the lung, liver carcinoma, breast cancer, and esophageal cancer. It has been used to characterize the source of various neoplasms and to study the distribution of cytokeratin containing cells in epithelia during normal development and during the development of epithelial neoplasms. This antibody stains cytokeratins present in normal and abnormal human tissues and has shown high sensitivity in the recognition of epithelial cells and carcinomas. |
|||
Pan Cytokeratin Antibody Cocktail (Acidic + Basic) |
|||
| V3051-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This antibody cocktail recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, which include Keratins 1, 3, 4, 5, 6, 8, 10, 14, 15, 16, and 19. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis. KRTL/KRTH is a broad spectrum anti pan-cytokeratin antibody cocktail, which differentiates epithelial tumors from non-epithelial tumors e.g. squamous vs. adenocarcinoma of the lung, liver carcinoma, breast cancer, and esophageal cancer. It has been used to characterize the source of various neoplasms and to study the distribution of cytokeratin containing cells in epithelia during normal development and during the development of epithelial neoplasms. This antibody stains cytokeratins present in normal and abnormal human tissues and has shown high sensitivity in the recognition of epithelial cells and carcinomas. |
|||
Pan Cytokeratin Antibody Cocktail (Acidic + Basic) |
|||
| V3051-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This antibody cocktail recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, which include Keratins 1, 3, 4, 5, 6, 8, 10, 14, 15, 16, and 19. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis. KRTL/KRTH is a broad spectrum anti pan-cytokeratin antibody cocktail, which differentiates epithelial tumors from non-epithelial tumors e.g. squamous vs. adenocarcinoma of the lung, liver carcinoma, breast cancer, and esophageal cancer. It has been used to characterize the source of various neoplasms and to study the distribution of cytokeratin containing cells in epithelia during normal development and during the development of epithelial neoplasms. This antibody stains cytokeratins present in normal and abnormal human tissues and has shown high sensitivity in the recognition of epithelial cells and carcinomas. |
|||
Pan Cytokeratin Antibody Cocktail (Acidic + Basic) |
|||
| V3051IHC-7ML | NSJ Bioreagents | 7 ml | EUR 499 |
|
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This antibody cocktail recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, which include Keratins 1, 3, 4, 5, 6, 8, 10, 14, 15, 16, and 19. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis. KRTL/KRTH is a broad spectrum anti pan-cytokeratin antibody cocktail, which differentiates epithelial tumors from non-epithelial tumors e.g. squamous vs. adenocarcinoma of the lung, liver carcinoma, breast cancer, and esophageal cancer. It has been used to characterize the source of various neoplasms and to study the distribution of cytokeratin containing cells in epithelia during normal development and during the development of epithelial neoplasms. This antibody stains cytokeratins present in normal and abnormal human tissues and has shown high sensitivity in the recognition of epithelial cells and carcinomas. |
|||
Pan Cytokeratin Antibody Cocktail (Acidic + Basic) |
|||
| V3051SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This antibody cocktail recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, which include Keratins 1, 3, 4, 5, 6, 8, 10, 14, 15, 16, and 19. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis. KRTL/KRTH is a broad spectrum anti pan-cytokeratin antibody cocktail, which differentiates epithelial tumors from non-epithelial tumors e.g. squamous vs. adenocarcinoma of the lung, liver carcinoma, breast cancer, and esophageal cancer. It has been used to characterize the source of various neoplasms and to study the distribution of cytokeratin containing cells in epithelia during normal development and during the development of epithelial neoplasms. This antibody stains cytokeratins present in normal and abnormal human tissues and has shown high sensitivity in the recognition of epithelial cells and carcinomas. |
|||
Pan Cytokeratin Antibody Cocktail (Acidic + Basic) |
|||
| V3070-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This antibody cocktail recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, with 67kDa (CK1); 64kDa (CK3); 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 55kDa (CK7); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13); 50kDa (CK14); 50kDa (CK15); 48kDa (CK16); 46kDa (CK17); 45kDa (CK18) and 40kDa (CK19). Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis. KRT-PAN is a broad spectrum anti pan-cytokeratin antibody cocktail, which differentiates epithelial tumors from non-epithelial tumors e.g. squamous vs. adenocarcinoma of the lung, liver carcinoma, breast cancer, and esophageal cancer. It is useful in characterizing the source of various neoplasms and to study the distribution of cytokeratin containing cells in epithelia during normal development and during the development of epithelial neoplasms. This antibody stains cytokeratins present in normal and abnormal human tissues and shows high sensitivity in the recognition of epithelial cells and carcinomas. |
|||
Pan Cytokeratin Antibody Cocktail (Acidic + Basic) |
|||
| V3070-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This antibody cocktail recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, with 67kDa (CK1); 64kDa (CK3); 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 55kDa (CK7); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13); 50kDa (CK14); 50kDa (CK15); 48kDa (CK16); 46kDa (CK17); 45kDa (CK18) and 40kDa (CK19). Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis. KRT-PAN is a broad spectrum anti pan-cytokeratin antibody cocktail, which differentiates epithelial tumors from non-epithelial tumors e.g. squamous vs. adenocarcinoma of the lung, liver carcinoma, breast cancer, and esophageal cancer. It is useful in characterizing the source of various neoplasms and to study the distribution of cytokeratin containing cells in epithelia during normal development and during the development of epithelial neoplasms. This antibody stains cytokeratins present in normal and abnormal human tissues and shows high sensitivity in the recognition of epithelial cells and carcinomas. |
|||
Pan Cytokeratin Antibody Cocktail (Acidic + Basic) |
|||
| V3070IHC-7ML | NSJ Bioreagents | 7 ml | EUR 499 |
|
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This antibody cocktail recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, with 67kDa (CK1); 64kDa (CK3); 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 55kDa (CK7); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13); 50kDa (CK14); 50kDa (CK15); 48kDa (CK16); 46kDa (CK17); 45kDa (CK18) and 40kDa (CK19). Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis. KRT-PAN is a broad spectrum anti pan-cytokeratin antibody cocktail, which differentiates epithelial tumors from non-epithelial tumors e.g. squamous vs. adenocarcinoma of the lung, liver carcinoma, breast cancer, and esophageal cancer. It is useful in characterizing the source of various neoplasms and to study the distribution of cytokeratin containing cells in epithelia during normal development and during the development of epithelial neoplasms. This antibody stains cytokeratins present in normal and abnormal human tissues and shows high sensitivity in the recognition of epithelial cells and carcinomas. |
|||
Pan Cytokeratin Antibody Cocktail (Acidic + Basic) |
|||
| V3070SAF-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This antibody cocktail recognizes acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins, with 67kDa (CK1); 64kDa (CK3); 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 55kDa (CK7); 52kDa (CK8); 56.5kDa (CK10); 53kDa (CK13); 50kDa (CK14); 50kDa (CK15); 48kDa (CK16); 46kDa (CK17); 45kDa (CK18) and 40kDa (CK19). Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis. KRT-PAN is a broad spectrum anti pan-cytokeratin antibody cocktail, which differentiates epithelial tumors from non-epithelial tumors e.g. squamous vs. adenocarcinoma of the lung, liver carcinoma, breast cancer, and esophageal cancer. It is useful in characterizing the source of various neoplasms and to study the distribution of cytokeratin containing cells in epithelia during normal development and during the development of epithelial neoplasms. This antibody stains cytokeratins present in normal and abnormal human tissues and shows high sensitivity in the recognition of epithelial cells and carcinomas. |
|||
Pan Cytokeratin Antibody Cocktail (Acidic + Basic) |
|||
| V3490-100UG | NSJ Bioreagents | 100 ug | EUR 499 |
|
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This antibody detects acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins: 67kDa (CK1); 64kDa (CK3); 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 50kDa (CK14); 50kDa (CK15); 48kDa (CK16); 40kDa (CK19). Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis. It is a broad spectrum anti pan-cytokeratin antibody, which differentiates epithelial tumors from non-epithelial tumors e.g. squamous vs. adenocarcinoma of the lung, liver carcinoma, breast cancer, and esophageal cancer. It may be useful to characterize the source of various neoplasms and to study the distribution of cytokeratin containing cells in epithelia during normal development and during the development of epithelial neoplasms. This antibody stains cytokeratins present in normal and abnormal human tissues and has high sensitivity in the recognition of epithelial cells and carcinomas. |
|||
Pan Cytokeratin Antibody Cocktail (Acidic + Basic) |
|||
| V3490-20UG | NSJ Bioreagents | 20 ug | EUR 219 |
|
Description: Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. This antibody detects acidic (Type I or LMW) and basic (Type II or HMW) cytokeratins: 67kDa (CK1); 64kDa (CK3); 59kDa (CK4); 58kDa (CK5); 56kDa (CK6); 52kDa (CK8); 56.5kDa (CK10); 50kDa (CK14); 50kDa (CK15); 48kDa (CK16); 40kDa (CK19). Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis. It is a broad spectrum anti pan-cytokeratin antibody, which differentiates epithelial tumors from non-epithelial tumors e.g. squamous vs. adenocarcinoma of the lung, liver carcinoma, breast cancer, and esophageal cancer. It may be useful to characterize the source of various neoplasms and to study the distribution of cytokeratin containing cells in epithelia during normal development and during the development of epithelial neoplasms. This antibody stains cytokeratins present in normal and abnormal human tissues and has high sensitivity in the recognition of epithelial cells and carcinomas. |
|||
Their depend achieved an space beneath the receiver working attribute curve (AUC) of 0.82, whole space (AUC = 0.77), common measurement (AUC = 0.63), and circularity (AUC = 0.62). In conclusion, by use of computational picture evaluation as a hypothesis-free discovery software, this research reveals the histomorphological marker with a excessive prognostic worth that’s easy and due to this fact straightforward to quantify by visible microscopy.
